- Diplomat's Jennifer Hagerman named president-elect of Michigan Pharmacists Association for 2014
- Diplomat becomes distributor of recently approved cancer drug
- Diplomat launches online specialty pharmacy resource targeting both patients and clinicians
- Diplomat Specialty Pharmacy initiates content partnership with NASP
- Diplomat added to limited-distribution network for Cornerstone Therapeutics' Bethkis
FLINT, Mich. — Diplomat Specialty Pharmacy has received limited distribution rights for a neovascular age-related macular degeneration treatment.
The specialty pharmacy chain said it has received distribution of Eylea (aflibercept) injection from Regeneron Pharmaceuticals, the drug's manufacturer. Macular degeneration is diagnosed as either nonvascular (dry) or vascular (wet) and is a leading cause of blindness in older adults. The vascular AMD usually leads to more serious vision loss, Diplomat said.
"Eylea represents an important new therapy in the treatment of AMD," Diplomat president and CEO Phil Hagerman said. "AMD is becoming more and more prevalent in Americans 60 years of age and older; Diplomat looks forward to providing services to help treat this growing population of patients to slow the progression of this disease."